GlassScriptPhysician profile
Joo Jang
NPI 1295349058
$1,543.27
in general payments reported to CMS, 2019-2025
23 companies · $369 in 2025
The $369 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $74.32 · 2022: $307 · 2023: $147 · 2024: $646 · 2025: $369.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,136 · Education: $25.56.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,136.21 |
| Education | $25.56 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $445.80 | 2022-2025 | Evenity, Prolia, Otezla |
| Astrazeneca Pharmaceuticals LP | $204.48 | 2022-2024 | Farxiga, Breztri, Airsupra |
| Novo Nordisk INC | $178.81 | 2021-2025 | Rybelsus, Ozempic, Wegovy |
| Lilly USA, LLC | $154.61 | 2021-2025 | Mounjaro, Jardiance, Zepbound |
| Ibsa Pharma INC. | $75.22 | 2022-2025 | Licart, Tirosint, Flector |
| Boehringer Ingelheim Pharmaceuticals, INC. | $66.11 | 2021-2023 | Tradjenta, Jardiance |
| Nestle Healthcare Nutrition INC. | $57.33 | 2022 | |
| Otsuka America Pharmaceutical, INC. | $37.60 | 2024-2025 | Rexulti |
| Scilex Pharmaceuticals INC. | $34.06 | 2023-2024 | Ztlido |
| Aimmune Therapeutics, INC. | $32.24 | 2024-2025 | Zenpep |
| Novartis Pharmaceuticals Corporation | $31.92 | 2023 | |
| Azurity Pharmaceuticals, INC. | $31.72 | 2023-2024 | Edarbi, Horizant |
| Abbvie INC. | $28.81 | 2022-2024 | |
| Arbor Pharmaceuticals, INC. | $24.34 | 2022 | |
| Ani Pharmaceuticals, INC. | $20.91 | 2025 | Purified Cortrophin Gel |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sumitomo Pharma America, INC. | $19.14 | 2023 | Gemtesa |
| Averitas Pharma INC. | $15.79 | 2025 | Qutenza |
| Gilead Sciences, INC. | $14.72 | 2022 | |
| Almatica Pharma LLC | $14.54 | 2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $14.12 | 2021 | |
| Amarin Pharma, INC. | $14.06 | 2022 | |
| Vivus LLC | $13.80 | 2024 | Pancreaze |
| Horizon Therapeutics Plc | $13.14 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Joo Jang listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.